Journal of Advances in Clinical Nursing

Objective Observe the effect of recombinant human brain natriuretic peptide treatment on refractory heart failure. Methods In this study, 60 patients with refractory heart failure who received treatment at our hospital between January and December 2022 were selected. Randomly assign patients to two groups, each with 30 people. One group will receive standard heart failure treatment as the control group, and the other group will be the observation group. Recombinant human brain natriuretic peptide therapy will be added to the standard treatment. The treatment period is three months, followed by evaluation and comparison of cardiac function parameters and incidence of adverse reactions between the two groups of patients. Results The improvement of cardiac function parameters in the observation group was significantly better than that in the control group, and this difference was statistically significant (p<0.05); Moreover, the number of adverse reactions encountered by the observation group was significantly lower than that of the control group, and this difference was also statistically significant. (p<0.05). Conclusion Recombinant human brain natriuretic peptide has a significant effect in the treatment of refractory heart failure, which can effectively improve the heart function of patients with a low incidence of adverse reactions, and is worthy of clinical practice application.

Recombinant human brain natriuretic peptide; Refractory heart failure; Therapeutic effect